Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

Pelvic floor muscle training effective for adult women with urinary incontinence

A type of exercise called pelvic floor muscle training is effective for treating adult women with urinary incontinence (the involuntary loss of urine) without risk of side effects, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality (AHRQ). The report also found that drug-based treatments can be effective, but the degree of benefit is low and side effects are common.

11 Apr 2012

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.

29 Mar 2012

Novel device for measuring pelvic floor muscle strength

It is estimated that urine loss affects 30% of women at some point in their lives. Despite this high incidence rate, up until now clinical evaluation of patients suffering from this problem has been based on tactile examination, a subjective procedure that is not carried out in a consistent way by different medical professionals.

26 Mar 2012

Women more likely to experience UI following vaginal delivery

Women are nearly three times more likely to experience urinary incontinence for more than 10 years following a vaginal delivery rather than a caesarean section, finds new research at the Sahlgrenska Academy at the University of Gothenburg, Sweden.

26 Mar 2012

New embolization procedure may bring hope to men with enlarged prostate

A new interventional radiology treatment, prostatic artery embolization, may bring hope to men with debilitating symptoms caused by an enlarged prostate, say the group of researchers who pioneered its use.

26 Mar 2012

CBT, PE can ameliorate treatment-induced menopausal symptoms in breast cancer patients

Researchers from The Netherlands have found that the menopausal symptoms caused by giving chemotherapy or hormonal therapy to younger women with breast cancer can be ameliorated considerably through the use of cognitive behavioural therapy (CBT) and physical exercise.

23 Mar 2012

NAFC honors VUMC nurse practitioner with Rodney Appell Continence Care Champion Award

The National Association For Continence (NAFC) presented Margaret "Amy" Hull, RNC, MSN, WHCNP, with its Rodney Appell Continence Care Champion Award at the Society of Urologic Nurses and Associates (SUNA) annual awards luncheon on March 3, 2012 held during the 2012 SUNA Annual Symposium in San Francisco.

21 Mar 2012

New UCLA Alzheimer's and Dementia Care program for patients, caregivers

Alzheimer's disease affects an estimated 5.4 million people in the U.S., some 480,000 of them in California. Nearly half of all people 85 and older will be stricken with the disease. The overall burden of dementia is still higher, with Alzheimer's accounting for only 60 to 80 percent of dementia cases.

15 Mar 2012

Botox - a potential for therapy of weak bladders in women

The study, published in the journal European Urology, was carried out at eight uro-gynecology centers in the UK from 2006 to 2009 by researchers from the University of Leicester. A total of 240 women were split into two groups, with 122 women given Botox and 118 receiving a dummy treatment. Researchers found improvements across a range of symptoms, including wetting oneself and feeling a need to rush to the toilet, and how often the women 'leaked' urine.

13 Mar 2012

Botulinum toxin effective in treating OAB among women

The biggest study into the treatment of urinary incontinence with botulinum toxin (trade name Botox) has demonstrated that it is effective in treating overactive bladder (OAB) - a debilitating common condition which can affect up to 20% of people over the age of 40.

12 Mar 2012

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo Pharmaceuticals today reported financial results for the fourth quarter of 2011.

24 Feb 2012

U.S. FDA accepts Pfizer's tafamidis NDA for treatment of TTR-FAP

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine, the company's investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy.

16 Feb 2012

Link between vitamin D deficiency and urinary incontinence

Vitamin D deficiency is higher among certain demographic segments, including women, the elderly, and the obese. All three groups also share an increased risk of pelvic floor problems, including urinary incontinence. Could there be a connection? Perhaps so, according to recent research.

12 Dec 2011

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Pfizer Inc. announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 - Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder.

6 Dec 2011

Women with overactive bladder invited for virtual research study

If you, or someone you know suffers from overactive bladder (otherwise known as OAB or "urge incontinence"), you might qualify for a research study of an approved medication where you can participate from the privacy and comfort of your own home.

2 Dec 2011

EC approves Pfizer's Vyndaqel to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer announced today that the European Commission has approved Vyndaqel (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy.

17 Nov 2011

New possibilities for relief from digestive diseases

As a researcher in neurogastroenterology for 40 years, professor Khalil Bitar has spent his professional life studying the causes of perplexing and what frequently become embarrassing problems for humans—issues such as constipation, diarrhea and colon disease.

17 Nov 2011

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Pfizer Inc. announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency.

9 Nov 2011

NIH selects Women & Infants to participate in Pelvic Floor Disorders Network

Women & Infants Hospital of Rhode Island has been selected by the National Institutes of Health (NIH) to participate in the national Pelvic Floor Disorders Network (PFDN). Women & Infants is one of just eight medical centers from across the US, and the only one in the Northeast, to work collaboratively to develop and perform research studies related to women with pelvic floor disorders.

21 Oct 2011

Highly prevalent urinary and bladder symptoms will increase further

Nearly half of all adults over 20 will experience at least one lower urinary tract symptom by 2018 - an estimated 2.3 billion people and a worldwide increase of 18% in just one decade - according to research in the October issue of the urology journal BJUI.

28 Sep 2011